Clinical Resource Use in Patients Undergoing Intradetrusor Abotulinum Toxin A Injections for Neurogenic Compared to Non‐Neurogenic Indications—The Potential for Compensation Inequities for Urologic and Urogynecologic Practices
Neurourology and Urodynamics · 28.07.2026
DOI: 10.1002/nau.70392 ↗Kurz gefasst
Fachartikel in der Zeitschrift Neurourology and Urodynamics, online erschienen am 28.07.2026. Verfasst von Manu Saravanan und 1 weiteren Autor:innen. Beteiligte Einrichtung: Virginia Commonwealth University School of Medicine, Richmond, Virginia, USA. Die Arbeit nennt 14 Literaturangaben.
Abstract (Originalsprache)
Introduction
Intradetrusor abotulinum toxin A (BoNT‐A) injections effectively manage urinary urgency, frequency, and urinary incontinence in patients with both overactive bladder (OAB) and neurogenic lower urinary tract dysfunction (NLUTD). However, NLUTD patients often require increased staffing support and extended procedure times compared to OAB patients. This study aims to quantify resource utilization differences between the two populations undergoing cystoscopic BoNT‐A treatment where only one Current Procedural Terminology Code (CPT 52287) exists.
Methods
We prospectively collected data at a tertiary urology clinic over 6 months on patients undergoing cystoscopic intradetrusor BoNT‐A injection. Nursing/medical assistant (RN/MA) time, physician time, room occupancy duration, and staffing numbers were documented.
Results
Sixty‐five patients (NLUTD = 44 and OAB = 21) were included. NLUTD patients when compared to OAB patients required significantly greater RN/MA time (72 min vs. 48 min, p < 0.001), extended room occupancy (51 min vs. 43 min, p = 0.013), and RN/MA staff per procedure (2.4 vs. 1.9 RN/MA's, p < 0.001). Physician times, while statistically different, were clinically similar (9 min vs 7 min, p = 0.008).
Conclusion
When comparing a NLUTD to an OAB population undergoing intradetrusor BoNT‐A injections, current procedural billing codes do not reflect the substantial differences in auxiliary staff requirements or room occupancy times. The absence of nuanced reimbursement mechanisms may foster avoidance of resource‐intensive patient populations and their medical access. Our findings underscore the potential need to consider implementing novel reimbursement strategies to ensure equitable access to care.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Virginia Commonwealth University School of Medicine, Richmond, Virginia, USA.
- Santa Clara Valley Medical Center, Division of Urology, San Jose, California, USA.
- Department of Urology, Stanford University Medical Center, San Jose, California, USA.
ORCID-Profile: Christopher S Elliott
Zitieren
APA
Saravanan, M., & Elliott, C. S. (2026). Clinical Resource Use in Patients Undergoing Intradetrusor Abotulinum Toxin A Injections for Neurogenic Compared to Non‐Neurogenic Indications—The Potential for Compensation Inequities for Urologic and Urogynecologic Practices. Neurourology and Urodynamics. https://doi.org/10.1002/nau.70392
Vancouver
Saravanan M, Elliott CS. Clinical Resource Use in Patients Undergoing Intradetrusor Abotulinum Toxin A Injections for Neurogenic Compared to Non‐Neurogenic Indications—The Potential for Compensation Inequities for Urologic and Urogynecologic Practices. Neurourology and Urodynamics. 2026. doi:10.1002/nau.70392
BibTeX
@article{Saravanan2026,
author = {Saravanan, Manu and Elliott, Christopher S},
title = {Clinical Resource Use in Patients Undergoing Intradetrusor Abotulinum Toxin A Injections for Neurogenic Compared to Non‐Neurogenic Indications—The Potential for Compensation Inequities for Urologic and Urogynecologic Practices},
journal = {Neurourology and Urodynamics},
year = {2026},
doi = {10.1002/nau.70392}
}
EUVIMED